Roussos Torres, Evanthia.T. http://orcid.org/0000-0002-0740-5102
Ho, Won J. http://orcid.org/0000-0003-2644-5086
Danilova, Ludmila
Tandurella, Joseph A. http://orcid.org/0000-0002-5806-6681
Leatherman, James
Rafie, Christine
Wang, Chenguang
Brufsky, Adam http://orcid.org/0000-0001-8080-7960
LoRusso, Patricia http://orcid.org/0000-0001-7144-036X
Chung, Vincent
Yuan, Yuan
Downs, Melinda
O’Connor, Ashley
Shin, Sarah M.
Hernandez, Alexei
Engle, Elizabeth L. http://orcid.org/0000-0002-6375-9060
Piekarz, Richard
Streicher, Howard
Talebi, Zahra http://orcid.org/0000-0001-9166-5160
Rudek, Michelle A. http://orcid.org/0000-0001-5739-6868
Zhu, Qingfeng http://orcid.org/0000-0001-7871-3359
Anders, Robert A. http://orcid.org/0000-0002-2363-9072
Cimino-Mathews, Ashley http://orcid.org/0000-0002-0638-7969
Fertig, Elana J. http://orcid.org/0000-0003-3204-342X
Jaffee, Elizabeth M. http://orcid.org/0000-0003-3841-6549
Stearns, Vered
Connolly, Roisin M. http://orcid.org/0000-0003-0056-1070
Funding for this research was provided by:
Tower Cancer Research Foundation
Concern Foundation
METAvivor
V Foundation for Cancer Research
Commonwealth Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA014089, P30CA006973, P30CA006973, P30CA006973, P30CA006973, P30CA006973, P30CA006973, P30CA006973, UM1CA186690, UM1CA186691, UM1CA186689, UM1CA186717, P30CA006973, P30CA006973, P30CA006973, P30CA006973, P30CA006973, UM1CA186691, P30CA006973, P30CA006973, P30CA006973, P30CA006973, P30CA006973, P30CA006973, P30CA006973)
Breast Cancer Research Foundation
Mary Kay Foundation
Article History
Received: 15 August 2023
Accepted: 17 January 2024
First Online: 14 February 2024
Competing interests
: R.M.C. has received an unrestricted educational grant from Pfizer and research funding for clinical trials from MSD Ireland, Pfizer, Daiichi Sankyo and AstraZeneca, all to her institution. R.M.C. has consulted for AstraZeneca/Daichii, Gilead and Seagen and has received travel support from Novartis. M.A.R. has received research grants to the institution from Celgene, Cullinan Apollo and RenovoRx and is a cofounder and board member and holds equity in Geminus Therapeutics. M.A.R.’s spouse is employed by GlaxoSmithKline. V.S. received research grants to their institution from Abbvie, Biocept, Pfizer, Novartis and Puma Biotechnology and is a member of the Data Safety Monitoring Board at Immunomedics and AstraZeneca. A.C.-M. has received research grants to their institution from HeritX, Genentech and Bristol Myers Squibb and serves as a consultant to Bristol Myers Squibb. A.B. is a paid consultant for Lilly, Novartis, Pfizer, Astrazeneca, Eisai, Roche and Sanofi. P.L.R. reports personal fees from Abbvie, Agios, Five Prime, GenMab, Halozyme, Roche-Genentech, Genentech, Cytomx, Takeda, SOTIO, Cybrexa, Agenus, Tyme, IQVIA, TRIGR, Pfizer, ImmunoMet, Black Diamond, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics, Kyowa Kirin, Kineta, Zentalis, Molecular Templates, ABL Bio, SK Life Science and STCube; these are all outside the submitted work. E.M.J. reports ongoing collaboration with Roche on new approaches to Precision Medicine Tumor Boards. V.C. is part of the speaker’s bureau for Ipsen and Coherus and is a Perthera and Pfizer consultant. Y.Y. is part of the speaker’s bureau for Gilead, AstraZeneca, Daiichi Sankyo and Merck, is a paid consultant for Gilead, Pfizer, Stemline and AstraZeneca and has received research support from Genentech, Merck, Pfizer, Imugene, Agenus and Gateway Foundation. R.A.A. has received research support from Bristol Myers Squibb, Merck, StandUp2Cancer and FLXbio and is a paid consultant for Bristol Myers Squibb, Merck, Incyte, AstraZeneca and FLXbio. E.J.F. is on the Scientific Advisory Board of Resistance Bio/Viosera Therapeutics and is a paid consultant for Merck and Mestag Therapeutics. E.M.J. is a paid consultant for Adaptive Biotech, CSTONE, Achilles, DragonFly and Genocea. E.M.J. receives funding from Lustgarten Foundation and Bristol Myers Squibb and is the Chief Medical Advisor for Lustgarten and a Scientific Advisory Board member for Parker Institute for Cancer Immunotherapy and C3 Cancer Institute. E.M.J. reports other support from Abmeta and Adventris, personal fees from Achilles, Dragonfly, Mestag, The Medical Home Group and Surgtx, other support from Parker Institute and grants and other support from the Lustgarten Foundation, Genentech, Bristol Myers Squibb and Break Through Cancer outside the submitted work. E.T.R.T. is a consultant for Synaptical and is a shareholder in this company. All other authors have nothing to disclose.